A Lithuanian startup called Vital3D is pioneering the future of organ printing with a strong foundation in regenerative medicine.
Currently, they are focusing on producing 3D-printed skin for veterinary use, marking their first commercial step toward more ambitious goals like bioprinting human organs.
Their first product, VitalHeal, is a bioprinted wound patch made using a proprietary laser-based 3D printing system.
This system accurately places living cells and biomaterials in layers to replicate the natural structure of tissue.
VitalHeal is designed to treat skin injuries in pets, significantly reducing healing time from 12 weeks to just 4–6 weeks, and lowering infection risks and medical intervention needs.
Despite their current focus on animals, Vital3D’s long-term mission is to create functional human organs within the next 10 to 15 years.
However, this ambitious goal faces technical hurdles, primarily vascularization (building networks of blood vessels) and the integration of various cell types essential for functioning organs.
CEO Vidmantas Šakalys, with a background in laser technology and biomedical devices, believes commercial products like VitalHeal will help fund research needed to overcome these barriers.
Vital3D is not just looking at transplants but also envisions applications in personalized medicine and advanced tissue engineering—efforts that could drastically address the global shortage of transplantable organs, where less than 10% of patients currently receive the organs they need.
Currently, they are focusing on producing 3D-printed skin for veterinary use, marking their first commercial step toward more ambitious goals like bioprinting human organs.
Their first product, VitalHeal, is a bioprinted wound patch made using a proprietary laser-based 3D printing system.
This system accurately places living cells and biomaterials in layers to replicate the natural structure of tissue.
VitalHeal is designed to treat skin injuries in pets, significantly reducing healing time from 12 weeks to just 4–6 weeks, and lowering infection risks and medical intervention needs.
Despite their current focus on animals, Vital3D’s long-term mission is to create functional human organs within the next 10 to 15 years.
However, this ambitious goal faces technical hurdles, primarily vascularization (building networks of blood vessels) and the integration of various cell types essential for functioning organs.
CEO Vidmantas Šakalys, with a background in laser technology and biomedical devices, believes commercial products like VitalHeal will help fund research needed to overcome these barriers.
Vital3D is not just looking at transplants but also envisions applications in personalized medicine and advanced tissue engineering—efforts that could drastically address the global shortage of transplantable organs, where less than 10% of patients currently receive the organs they need.
A Lithuanian startup called Vital3D is pioneering the future of organ printing with a strong foundation in regenerative medicine.
Currently, they are focusing on producing 3D-printed skin for veterinary use, marking their first commercial step toward more ambitious goals like bioprinting human organs.
Their first product, VitalHeal, is a bioprinted wound patch made using a proprietary laser-based 3D printing system.
This system accurately places living cells and biomaterials in layers to replicate the natural structure of tissue.
VitalHeal is designed to treat skin injuries in pets, significantly reducing healing time from 12 weeks to just 4–6 weeks, and lowering infection risks and medical intervention needs.
Despite their current focus on animals, Vital3D’s long-term mission is to create functional human organs within the next 10 to 15 years.
However, this ambitious goal faces technical hurdles, primarily vascularization (building networks of blood vessels) and the integration of various cell types essential for functioning organs.
CEO Vidmantas Šakalys, with a background in laser technology and biomedical devices, believes commercial products like VitalHeal will help fund research needed to overcome these barriers.
Vital3D is not just looking at transplants but also envisions applications in personalized medicine and advanced tissue engineering—efforts that could drastically address the global shortage of transplantable organs, where less than 10% of patients currently receive the organs they need.
